A randomized, observer-blind, active-controlled phase III study to demonstrate the superior efficacy of GSK Biologicals' adjuvanted influenza candidate vaccine [GSK2186877A], administered intramuscularly in elderly aged 65 years or above, as compared to Fluarix

Trial Profile

A randomized, observer-blind, active-controlled phase III study to demonstrate the superior efficacy of GSK Biologicals' adjuvanted influenza candidate vaccine [GSK2186877A], administered intramuscularly in elderly aged 65 years or above, as compared to Fluarix

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Influenza virus vaccine (Primary) ; AS03A
  • Indications Influenza A virus infections; Influenza B virus infections
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms INFLUENCE 65
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals
  • Most Recent Events

    • 18 Jun 2012 Actual patient number changed from 43812 to 43695 as reported by ClinicalTrials.gov.
    • 28 Mar 2011 Actual end date changed from May 2010 to Dec 2010 as reported by ClinicalTrials.gov.
    • 28 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top